HCW Biologics announces full exercise of pre-funded warrants by Armistice Capital

HCW Biologics Inc. (NASDAQ:HCWB) reported that Armistice Capital Master Fund Ltd. has fully exercised its pre-funded warrants to purchase shares of the company’s common stock. According to a press release statement in a U.S. Securities and Exchange Commission filing, Armistice exercised the remaining 54,000 pre-funded warrants on June 18, 2025.

The warrants were originally granted as part of a Securities Purchase Agreement dated May 13, 2025. They allowed Armistice to purchase up to 513,140 shares of HCW Biologics common stock at an exercise price of $0.0001 per share. Prior to June 18, Armistice had exercised warrants for a total of 459,140 shares. With the latest transaction, all pre-funded warrants under the agreement have now been exercised and none remain outstanding.

HCW Biologics is incorporated in Delaware and its principal executive offices are located in Miramar, Florida. The company’s common stock is listed on The Nasdaq Stock Market LLC under the symbol HCWB.

This information is based on a press release statement included in a recent SEC filing.

In other recent news, HCW Biologics Inc. announced the development of second-generation T-cell engagers targeting pancreatic cancer. These candidates have shown anti-cancer activity in laboratory tests and humanized mouse models. Additionally, the company has regained compliance with all Nasdaq Capital Market listing requirements, having satisfied the minimum stockholders’ equity requirement. In a significant partnership development, HCW Biologics entered a licensing agreement with WY Biotech for the novel immunotherapy molecule HCW11-006, receiving a $7.0 million upfront license fee. Furthermore, the company presented findings on HCW9206, a fusion protein that could enhance the efficacy and reduce the costs of CAR-T therapies. Despite these advancements, HCW Biologics faces legal challenges over alleged breach of contract related to its new headquarters’ construction. The lawsuit was filed by BE&K Building Group, seeking damages and costs. The company is also exploring alternative financing options to resolve financial issues linked to the construction project.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.